Comparative analysis of EAU, AUA, and NCCN guidelines for the management of non-muscle invasive bladder cancer

BACKGROUND: This study aimed to systematically compare the most recent guidelines from the European Association of Urology (EAU, 2025), American Urological Association (AUA, 2024), and National Comprehensive Cancer Network (NCCN, 2025) for the management of non-muscle invasive bladder cancer (NMIBC). The primary objective was to assess the degree of concordance and identify sources of divergence across 32 predefined clinical decision domains. MATERIALS AND METHODS: This guideline concordance study was conducted according to PRISMA 2020 recommendations, evaluating full-text versions of the latest EAU, AUA, and NCCN guidelines. Thirty-two clinical domains encompassing the diagnostic, therapeutic, and follow-up aspects of NMIBC management were pre-defined based on literature review and expert consensus. Two independent reviewers classified each domain for each guideline as full concordance, partial concordance, or discordance, with discrepancies resolved by a third reviewer. Inter-guideline agreement was quantified using Cohen's and Fleiss' kappa coefficients. RESULTS: Among the 32 domains analyzed, full concordance was identified in 19 domains (59.4%), partial concordance in 12 domains (37.5%), and discordance in 1 domain (3.1%). Inter-guideline reliability was high, with Cohen's kappa values ranging from 0.83 to 0.94 across pairs and an overall Fleiss' kappa of 0.74, indicating substantial agreement among the three guidelines. Clinically meaningful differences were mainly related to risk-stratification criteria, the management of BCG-unresponsive disease, the selective use of urinary biomarkers, and the endorsement of conservative strategies for recurrent low-grade tumors. CONCLUSION: Current international guidelines for NMIBC are highly consistent across the majority of clinical decision domains, providing a strong framework for evidence-based care. Residual differences reflect evolving evidence, regulatory environments, and the pace of integration of new diagnostics and therapeutics. Continued harmonization efforts and regular guideline updates are necessary to further optimize global NMIBC management.